Monitoring influenza virus oseltamivir resistance – our experience to date
Authors:
L. Nováková; M. Havlíčková
Authors‘ workplace:
Státní zdravotní ústav, Centrum epidemiologie a mikrobiologie, Praha
Published in:
Epidemiol. Mikrobiol. Imunol. 70, 2021, č. 4, s. 241-246
Category:
Original Papers
Overview
Objective: The monitoring of influenza virus resistance is a routine part of influenza virus surveillance conducted by the National Reference Laboratory for Influenza and Non-Influenza Respiratory Viral Diseases (NRL/INI) at the National Institute of Public Health (NIPH). The aim is to detect neuraminidase inhibitor (oseltamivir) resistance in patients diagnosed with influenza.
Material and methods: A total of 326 influenza virus isolates from tissue culture were included in the study. They were obtained from inpatient and outpatient nasopharyngeal swabs which were referred to the NRL/INI during the seasons 2013/2014 to 2019/2020 and turned out to be RTPCR (reverse transcription polymerase chain reaction) positive for RNA (ribonucleic acid) of influenza virus A or B. The MDCK (Madin-Darby canine kidney) tissue culture cells were used for virus isolation from nasopharyngeal swabs. Oseltamivir resistance was tested using the NA-Star Influenza Neuraminidase Inhibitor Resistance Detection Kit (Applied Biosystems, Foster City, CA).
Results: Nine of 326 positive specimens were oseltamivir resistant. Resistant strains showed IC50 values 100 times as high on average as those in oseltamivir sensitive strains.
Conclusions: Monitoring influenza virus resistance is helpful in controlling reasonable prescription of antivirals and thus becomes an integral part of influenza virus surveillance. Antiviral resistance monitoring is necessary not only in hospitalized patients on antivirals but also in symptomatically treated outpatients as the detection of antiviral drug resistant strains in the latter group can suggest the emergence and/or spread of antiviral drug resistance in the population.
Keywords:
surveillance – Mutation – resistance – influenza A and B – oseltamivir
Sources
1. Webster RG, Bean WJ, Gorman OT, et al. Evolution and ecology of influenza A viruses. Microbiological Reviews, 1992;56:152–179.
2. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. The Lancet, 2000;355:827–835.
3. Lamb RA, Krug RM. Orthomyxoviridae: The viruses and their replication. In: Knipe, DM, Howley PM, Griffin DE., Eds., Fields Virology, Lippincott Williams & Wilkins, 2001, 4th edition, pp. 1487–1531.
4. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses, 2012;7(1):25–36.
5. Li Q, Sun X, Li Z, et al. Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Proceedings of the National Academy of Sciences of the United States of America, 2012;109(46):18897–18902.
6. Wu Y, Wu Y, Tefsen B, et al. Bat-derived influenza-like viruses H17N10 and H18N11. Trends in Microbiology, 2014;22(4):183– 191.
7. Rosenberg MR, Casarotto MG. Coexistence of two adamantane binding sites in the influenza A M2 ion channel. PNAS, 2010;107(31):13866–13871.
8. Adabala PJ, LeGresley EB, Bance N, et al. Exploitation of the catalytic site and 150 cavity for design of influenza A neuraminidase inhibitors. The Journal of Organic Chemistry, 2013; 78(21):10867– 10877.
9. Singh A, Soliman ME. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyse. Drug Design, Development and Therapy, 2015;9:4137–4154.
10. Lampejo T. Influenza and antiviral resistence: an overview. European Journal of Clinical Microbiology & Infectious Diseases, 2020;39:1201–1208.
11. Státní ústav pro kontrolu léčiv [online]. Dostupné zwww: https://www.sukl.cz/.
12. Takashita E, Ejima M, Itoh R, et al. A community cluster of influenza A (H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013. Eurosurveillance, 2014;19(1):pii=20666. Dostupné na www: http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId= 20666.
13. Shobugawa Y, Saito R, Sato I, et al. Clinical effectiveness of neuraminidase inhibitors-oseltamivir, zanamivir, laninamivir and peramivir-for treatment of influenza A(H3N2) and A(H1N1) pdm09 infection: an observational study in the 2010-2011 influenza season in Japan. Journal of Infection and Chemotherapy, 2012;18(6):858–864.
14. Chong Y, Matsumoto S, Kang D, et al. Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistence in Japan. Influenza and Other Respiratory Viruses, 2019;13:115–122.
15. Yang T. Baloxavir marboxil: The first cap – dependent endonuclease inhibitor for the treatment of influenza. Annals of Pharmacotherapy, 2019;53(7):754–759.
16. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. The New England Journal of Medicine, 2018;379(10):913–923.
17. Li TCM, Chan MCW, Lee N. Clinical implication of antiviral resistence in influenza. Viruses, 2015;7(9):4929–4944.
18. Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T705), a novel viral RNA polymerase inhibitor. Antiviral Research, 2013;100:446–454.
19. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy Series, 2017;93(7):449–463.
20. Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID19. International Journal of Infectious Diseases, 2021;102:501–508.
21. Nagata T, Lefor AK, Hasegawa M, et al. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Medicine and Public Health Preparedness, 2015;9:79–81.
22. Belardo G, Cenciarelli O, La Frazia S, et al. Synergistic effect of nitazoxanide with neuraminidase inhibitors against influenza A viruses in vitro. Antimicrobial Agents and Chemotherapy, 2015;59:1061–1069.
23. Huang L, Zhang L, Liu Y, et al. Arbidol for preventing and treating influenza in adults and children. Cochrane Database of Systematic Reviews, 2015;1:1–9.
24. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in late – phase clinical trial. Influenza and Other Respiratory Viruses, 2017;11:240–246.
25. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Current Opinion in Infectious Diseases, 2019;32(2):176–186.
26. Neuraminidase inhibition assay (IC50). In International society for influenza and other respiratory virus diseases [online]. Dostupné na www: http://www.isirv.org/site/index.php/methodology/ nai-assay-ic50.
27. WHO. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility-Geneva, November 2011 and 2012. Weekly epidemiological record, 2012;87: 369–373.
28. MyAssays Analysis Software Solutions. In MyAssays. Analysis, solved [online]. Dostupné na www: http://www.myassays.com. aspx.
29. WHO. Manual for the laboratory diagnosis and virological surveillance of influenza [online]. 2011. ISBN 978 92 4 154809 0. Dostupné na www: http://apps.who.int/iris/bitstre am/10665/44518/1/9789241548090_eng.pdf.
30. Dong G, Peng C, Luo J, et al. Adamantane – resistant influenza A viruses in the world (1902–2013): frequency and distribution of M2 gene mutations. PLoS ONE, 2015;10(3):e0119115.
31. Moasser E, Moasser A, Zaraket H. Incidence of antiviral drug resistence markers among human influenza A viruses in the Eastern mediterranean region, 2005 – 2016. Infection, Genetics and Evolution, 2018;67:60–66.
32. Lackenby A, Hungnes O, Dudman SG, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveillance, 2008;13(5):pii=8026. Dostupné na www: https://doi.org/10.2807/ese.13.05.08026-en.
33. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrobial Agents and Chemotherapy, 2008;52(9):3284–3292.
34. Murtaugh W, Mahaman L, Healey B, et al. Evaluation of three influenza neuraminidase inhibition assays for use in a public health laboratory setting during the 2011–2012 influenza season. Public Health Reports, 2013;128:75–87.
35. Calatayud L, Lackenby A, Reynolds A, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009–2010. Emerging Infectious Diseases, 2011;17:1807–1815.
36. Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistence dutiny the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives. The Lancet Infectious Diseases, 2012;12:240–248.
Labels
Hygiene and epidemiology Medical virology Clinical microbiologyArticle was published in
Epidemiology, Microbiology, Immunology
2021 Issue 4
Most read in this issue
- Mumps and its occurrence in the Czech Republic and Slovakia
- Corynebacterium sp. isolated from blood culture of a bacteremic patient. Will the assumptions about a new corynebacterium be confirmed?
- Possibilities for the analysis of peripheral blood B cell subpopulations in a routine immunological laboratory
- Prevalence and management of arterial hypertension in the population aged 25–64 in the Czech Republic with a focus on diabetic patients